German Medtechs Search For Blue Skies Amid ‘Cloudy Outlook’ For Industry − Medica 2023

Regulatory compliance is no longer the only pressing issue for medtechs in Germany

 
• By Ashley Yeo
  
Generate a summary of this article
Listen to this article
Beta

While revenues are looking healthier at last, a host of issues in the post-COVID readjustment phase still weigh heavily on medtech manufacturers in Germany, chief among which is EU and national over-regulation. Hospital reform and the digital shift are also on a long list of priority issues to monitor and tackle if Germany’s industrial base is to remain preeminent, said BVMed chief executive Marc-Pierre Möll.

Storm clouds gather over the sea near castletownbere in county cork, republic of ireland, shot in october 2016. taken from the shore near the town beach. - Image

Marc-Pierre Möll joined German medtech industry association BVMed almost five years ago as chief executive. That was shortly after the Medical Device (2017/745) and IVD Regulation (2017/746) were implemented. They unleashed a thirst for information, support and advice in an industry sent reeling by an explosion of new regulatory requirements and costs, and confusion over precisely how to comply.

Under Möll, BVMed has expanded its membership by 28% to around 320, founded a Brussels office to field EU-related issues...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Germany

Dermanostic: A Legal Guinea Pig Impacted By MDR’s Regulatory Gaps?

 
• By Amanda Maxwell

With the latest ruling in Germany, there is speculation that the Medical Device Regulation’s confusing Article 11 on software or the device’s timing of gaining its class I category may be to blame for the invidious position Dermanostic has found itself in.

Why Notified Bodies Are Now The Focus Of Centralized Oversight Efforts

 
• By Amanda Maxwell

Proposals for substantial changes to oversight of medtech notified bodies are likely to be part of the European Commission’s targeted evaluation of the MDR and IVDR, EU medtech lawyer, Erik Vollebregt, tells Medtech Insight.

Amendment To MDR May Be First Legislative Proposal Of New European Commission

 
• By Amanda Maxwell

How Germany, which has the EU’s largest medtech manufacturing base, is pressing for the MDR to feature on the mission letter for the new European Commission and could influence the pace of change.

EU MDR Failings Aired At German Parliamentary Hearing

 
• By Ashley Yeo

MPs from across Germany’s political spectrum grilled a panel of national medtech stakeholders on the problems of the MDR and the EU regulatory system during an hour-long sitting of the Bundestag’s health committee on 5 June.

More from Europe

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Abbott’s Share-Gobbling Aveir DR Leadless Pacing System Introduced To UK

 
• By Natasha Barrow

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Amferia Aims To Bring Peptide Hydrogel To Fight Against Antimicrobial Resistance

 
• By Natasha Barrow

Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.